VAERS reports by lot
Sanofi Pasteur DTaP/Tdap lot U4335AA: VAERS reports
27 VAERS reports list lot U4335AA as a Sanofi Pasteur DTaP/Tdap vaccine, received between 2012-03-22 and 2013-06-07. Data: VAERS public files through 28 May 2026 (site extract 2026-10-28).
Symptom categories in these reports
A report can mention several categories, so the counts add up to more than the number of reports.
| Category | Count | % |
|---|---|---|
| Injection-site / Local reaction | 27 | 27% |
| General / Systemic (non-local) | 24 | 24% |
| Musculoskeletal | 16 | 16% |
| Neurological | 13 | 13% |
| Cardiac / Cardiovascular | 7 | 7% |
| Dermatological (non-injection-site) | 5 | 5% |
| Gastrointestinal | 4 | 4% |
| Allergic / Anaphylactic | 3 | 3% |
| Respiratory | 1 | 1% |
Where reports came from
U.S. state of the reporter, where given (top 12).
| State | Reports |
|---|---|
| California | 5 |
| Texas | 5 |
| Washington | 4 |
| Arizona | 2 |
| Montana | 1 |
| Wyoming | 1 |
| Louisiana | 1 |
| Idaho | 1 |
| North Carolina | 1 |
| Kansas | 1 |
| Tennessee | 1 |
| Missouri | 1 |
Reports by month received
| Month | Reports | Bar |
|---|---|---|
| 2012-03 | 1 | |
| 2012-04 | 1 | |
| 2012-05 | 2 | |
| 2012-06 | 4 | |
| 2012-07 | 4 | |
| 2012-08 | 4 | |
| 2012-09 | 3 | |
| 2012-10 | 2 | |
| 2012-11 | 4 | |
| 2012-12 | 1 | |
| 2013-06 | 1 |
Products recorded with this lot
- Tdap — Sanofi Pasteur (27 reports)
Manufacturer and product as reported in VAERS. Reports listing the lot under more than one product are counted once.
Related
- All Sanofi Pasteur DTaP/Tdap lots with VAERS reports
- DTaP/Tdap vaccine lot number lookup
- DTaP/Tdap vaccine side effects, trials and ingredients
- Daptacel: ingredients, package insert and side effects
- Look up a lot for any vaccine
Nearby Sanofi Pasteur DTaP/Tdap lots (A–Z): U3051AA · U4325AA · U4329AA · U4384AA · U4393BA · U4421AA
Source: VAERS public data (CDC/FDA), grouped by manufacturer and lot by the Open Source Medicine Foundation; extract 2026-10-28 18:08 UTC. Not medical advice. Report errors via contact.